CSIMarket
 


Renovorx Inc   (RNXT)
Other Ticker:  
 
 

RNXT's Income from Cont. Operations Growth by Quarter and Year

Renovorx Inc 's Income from Cont. Operations results by quarter and year




RNXT Income from Cont. Operations (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - 1.51 0.00 0.00
III Quarter September -2.14 -1.51 0.00 0.00
II Quarter June -2.59 0.00 0.00 0.00
I Quarter March -3.00 0.00 0.00 0.00
FY   -7.73 0.00 0.00 0.00



RNXT Income from Cont. Operations third quarter 2022 Y/Y Growth Comment
Renovorx Inc in the third quarter 2022 recorded loss from continued operations of $ -2.14 millions.

According to the results reported in the third quarter 2022, Renovorx Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Renovorx Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter 2022.




RNXT Income from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Renovorx Inc 's third quarter 2022 Income from Cont. Operations $ -2.14 millions RNXT's Income Statement
Renovorx Inc 's third quarter 2021 Income from Cont. Operations $ -1.51 millions Quarterly RNXT's Income Statement
New: More RNXT's historic Income from Cont. Operations Growth >>


RNXT Income from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Renovorx Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RNXT's III. Quarter Q/Q Income from Cont. Operations Comment
Despite the fact, that Renovorx Inc in the III. Quarter 2022 revealed loss from continued operations of $ -2.14 millions, it should be said, that current results show improvement in contrast to the -2.59 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Renovorx Inc achieved highest sequential Income from Cont. Operations growth. While Renovorx Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


RNXT's III. Quarter Q/Q Income from Cont. Operations Comment
Even if Renovorx Inc in the III. Quarter 2022 revealed loss from continued operations of $ -2.14 millions, some analyst said, that those numbers show slight up side relative to the -2.59 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Renovorx Inc achieved highest sequential Income from Cont. Operations growth. While Renovorx Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Renovorx Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Income from Cont. Operations 12 Months Ending $ -6.22 $ -5.60 $ 0.00 $ 0.00 $ 0.00
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Renovorx Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -6 millions in the Sep 30 2022 period.
The business is worsening as the cumulative loss from continued operations is inflating from $ -5.6 millions in the twelve months ending a quarter before and $ -2.59 millions from the TTM period ending Sep 30 2021.

Renovorx Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Renovorx Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -6 millions in the Sep 30 2022 period.
The business is getting worse as the cumulative loss from continued operations is inflating from $ -5.6 millions in the twelve months ending a quarter before and $ -2.59 millions for the twelve months ending in the quarter a year ago.

Renovorx Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
RNXT's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for RNXT's Competitors
Income from Cont. Operations Growth for Renovorx Inc 's Suppliers
Income from Cont. Operations Growth for RNXT's Customers

You may also want to know
RNXT's Annual Growth Rates RNXT's Profitability Ratios RNXT's Asset Turnover Ratio RNXT's Dividend Growth
RNXT's Roe RNXT's Valuation Ratios RNXT's Financial Strength Ratios RNXT's Dividend Payout Ratio
RNXT's Roa RNXT's Inventory Turnover Ratio RNXT's Growth Rates RNXT's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2022
Vir Biotechnology Inc 58.76%$ 58.757 millions
United Therapeutics Corporation47.08%$ 47.081 millions
Dexcom Inc 42.74%$ 42.736 millions
Pro dex Inc 42.14%$ 42.140 millions
Medpace Holdings Inc 35.93%$ 35.931 millions
Zimmer Biomet Holdings Inc 33.20%$ 33.196 millions
Iradimed Corporation33.03%$ 33.026 millions
Eli Lilly And Company30.77%$ 30.772 millions
Bio techne Corp30.09%$ 30.085 millions
Merit Medical Systems Inc27.62%$ 27.618 millions
Abbvie Inc 24.28%$ 24.277 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

TINV's Profile

Stock Price

TINV's Financials

Business Description

Fundamentals

Charts & Quotes

TINV's News

Suppliers

TINV's Competitors

Customers & Markets

Economic Indicators

TINV's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071